Evidence mapPaperPMID 40564936Full record

ReviewInternational journal of molecular sciences2025

The Role of miR-802 in Diabetic Kidney Disease: Diagnostic and Therapeutic Insights.

Antonio Tejera-Muñoz, Vanessa Marchant, Lucía Tejedor-Santamaría, Lucas Opazo-Ríos, Carolina Lavoz, María José Gimeno-Longas, José L Aceña, Marta Ruiz-Ortega, Raúl R Rodrigues-Díez

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antonio Tejera-MuñozDepartment of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante, Institute of Health and Biomedical Research of Alicante (ISABIAL), 03004 Alicante, Spain.ORCID 0000-0002-7954-5753
Vanessa MarchantCellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-2767-0229
Lucía Tejedor-SantamaríaCellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0003-4295-7284
Lucas Opazo-RíosFacultad de Ciencias de la Salud, Universidad de Las Américas, Concepción-Talcahuano 4301099, Chile.ORCID 0000-0003-3586-3319
Carolina LavozUnidad de Nefrología, Instituto de Medicina, Universidad Austral de Chile, Valdivia 5110566, Chile.
María José Gimeno-LongasDepartment of Cell Biology, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-2086-9534
José L AceñaDepartment of Organic and Inorganic Chemistry, Faculty of Pharmacy, University of Alcalá (IRYCIS), 28805 Madrid, Spain.
Marta Ruiz-OrtegaCellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-1495-6535
Raúl R Rodrigues-DíezDepartment of Cell Biology, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.

Funding

Carlos III Health Institute (ISCIII) and FEDER funds from the European Union PI20/00140; RICORS2040; RD21/0005/0002; RD21/0005/0005Comunidad Autónoma de Madrid INNOREN P2022/BMD-7221Spanish Society of Nephrology 2020
6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is a serious microvascular complication of diabetes mellitus and a leading cause of end-stage kidney disease. Despite its rising incidence, awareness and early detection of renal complications remain limited. Current research in DKD aims to identify non-invasive biomarkers for early diagnosis and to develop effective therapies that go beyond controlling risk factors, as few options are available to halt or reverse kidney inflammation and fibrosis. MicroRNAs (miRNAs), key regulators of gene expression, have emerged as promising candidates for both diagnosis and treatment in DKD. Among them, miR-802 has gained attention due to its role in modulating inflammatory, fibrotic, and metabolic pathways. Elevated levels of miR-802 correlate with renal inflammation and fibrosis in diabetic and obese models, highlighting its potential as both a diagnostic biomarker and a therapeutic target. This review focuses on the emerging evidence supporting the involvement of miR-802 in the pathogenesis of DKD and its potential role as a diagnostic and therapeutic tool. In addition, considering that miR-802 has also been implicated in other diseases, such as cancer, where it may act either as a tumor suppressor or an oncogene, these contrasting effects will also be discussed as part of the broader context to better understand the multifaceted biological roles of miR-802. This review emphasizes the need for further research to clarify the molecular mechanisms of miR-802 and to assess its potential for clinical translation in DKD.

Indexed as

Diabetic NephropathiesMicroRNAsAnimalsBiomarkersHumansBiomarkersMicroRNAsbiomarkersdiabetic kidney diseasemicroRNAsmiR-802therapeutic targets

Identifiers

PMID40564936
PMCPMC12193348

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.